MX2020003245A - Moleculas artificiales de acido nucleico. - Google Patents
Moleculas artificiales de acido nucleico.Info
- Publication number
- MX2020003245A MX2020003245A MX2020003245A MX2020003245A MX2020003245A MX 2020003245 A MX2020003245 A MX 2020003245A MX 2020003245 A MX2020003245 A MX 2020003245A MX 2020003245 A MX2020003245 A MX 2020003245A MX 2020003245 A MX2020003245 A MX 2020003245A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- utr
- artificial nucleic
- acid sequence
- acid molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a una molécula artificial de ácido nucleico que comprende al menos un marco de lectura abierto y al menos un elemento de región no traducida 3' (3'-UTR) que comprende una secuencia que se deriva de la 3'-UTR de un gen de proteína ribosómica. La invención se refiere adicionalmente al uso de tal molécula artificial de ácido nucleico en la terapia génica y/o vacunación genética. Adicionalmente, la invención se refiere al uso de un elemento 3'-UTR que comprende una secuencia de ácido nucleico que se deriva de la 3'-UTR de un gen de proteína ribosómica para mejorar, estabilizar y/o prolongar la expresión de proteínas de una secuencia de ácido nucleico que comprende tal elemento 3'-UTR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2013003946 | 2013-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003245A true MX2020003245A (es) | 2020-07-20 |
Family
ID=49920310
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008551A MX2016008551A (es) | 2013-12-30 | 2014-12-30 | Moleculas artificiales de acido nucleico. |
| MX2020003245A MX2020003245A (es) | 2013-12-30 | 2016-06-27 | Moleculas artificiales de acido nucleico. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008551A MX2016008551A (es) | 2013-12-30 | 2014-12-30 | Moleculas artificiales de acido nucleico. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10047375B2 (es) |
| JP (2) | JP6704850B2 (es) |
| KR (1) | KR102399799B1 (es) |
| CN (2) | CN111304231A (es) |
| AU (1) | AU2014375402B2 (es) |
| BR (1) | BR112016014462A2 (es) |
| CA (1) | CA2927862C (es) |
| DK (1) | DK3090053T3 (es) |
| ES (1) | ES2712092T3 (es) |
| MX (2) | MX2016008551A (es) |
| RU (1) | RU2717986C2 (es) |
| SG (2) | SG10201903381TA (es) |
| WO (1) | WO2015101414A2 (es) |
Families Citing this family (181)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| CA2866945C (en) * | 2012-03-27 | 2021-05-04 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| US9683233B2 (en) * | 2012-03-27 | 2017-06-20 | Curevac Ag | Artificial nucleic acid molecules for improved protein or peptide expression |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| CN105073135A (zh) | 2013-02-22 | 2015-11-18 | 库瑞瓦格有限责任公司 | 疫苗接种和抑制pd-1途径的组合 |
| WO2014152774A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Methods and compositions for delivering mrna coded antibodies |
| CN105142676B (zh) | 2013-03-14 | 2022-06-28 | 夏尔人类遗传性治疗公司 | Cftr mrna组合物以及相关方法和用途 |
| RS57316B1 (sr) | 2013-03-15 | 2018-08-31 | Translate Bio Inc | Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| EP3019619B1 (en) | 2013-07-11 | 2021-08-25 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| CN105451779A (zh) | 2013-08-21 | 2016-03-30 | 库瑞瓦格股份公司 | 增加rna编码蛋白表达的方法 |
| JP6896421B2 (ja) | 2013-08-21 | 2021-06-30 | キュアバック アーゲー | 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
| CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
| US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
| CA2927862C (en) | 2013-12-30 | 2024-01-23 | Curevac Ag | Artificial nucleic acid molecules |
| SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
| JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| JP6748579B2 (ja) | 2014-06-10 | 2020-09-02 | キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒｎａ生成を強化する方法及び手段 |
| ES2931832T3 (es) | 2014-06-25 | 2023-01-03 | Acuitas Therapeutics Inc | Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos |
| PL3708668T3 (pl) | 2014-12-12 | 2022-12-05 | Curevac Ag | Sztuczne cząsteczki kwasu nukleinowego dla poprawy ekspresji białka |
| CN107124889A (zh) * | 2014-12-30 | 2017-09-01 | 库瑞瓦格股份公司 | 人工核酸分子 |
| WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
| US10780054B2 (en) | 2015-04-17 | 2020-09-22 | Curevac Real Estate Gmbh | Lyophilization of RNA |
| RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| US11384375B2 (en) | 2015-04-30 | 2022-07-12 | Curevac Ag | Immobilized poly(n)polymerase |
| EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
| JP6893177B2 (ja) | 2015-05-15 | 2021-06-23 | キュアバック アーゲー | 少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ） |
| WO2016184575A1 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
| EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
| WO2016193226A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | Method for adding cap structures to rna using immobilized enzymes |
| ES2960429T3 (es) | 2015-05-29 | 2024-03-04 | Curevac Mfg Gmbh | Método para producir y purificar ARN, que comprende al menos una etapa de filtración de flujo tangencial |
| US10221127B2 (en) | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
| MX2018001040A (es) | 2015-08-28 | 2018-06-15 | Curevac Ag | Moleculas de acido nucleico artificiales. |
| CA2998370A1 (en) * | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a stabilizing tail region |
| SI3350157T1 (sl) | 2015-09-17 | 2022-04-29 | Modernatx, Inc. | Sestave za doziranje terapevtskih sredstev v celice |
| WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| US20190225644A1 (en) | 2015-10-16 | 2019-07-25 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
| SI3362461T1 (sl) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Analogi kape MRNA z modificirano fosfatno povezavo |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| DK3718565T3 (da) | 2015-10-22 | 2022-06-20 | Modernatx Inc | Vacciner mod respiratorisk virus |
| CA3003055C (en) | 2015-10-28 | 2023-08-01 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| US11684665B2 (en) | 2015-12-22 | 2023-06-27 | CureVac SE | Method for producing RNA molecule compositions |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| MX2018009917A (es) | 2016-02-17 | 2019-08-14 | Curevac Ag | Vacuna contra el virus del zika. |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| JP7150608B6 (ja) | 2016-04-08 | 2022-11-11 | トランスレイト バイオ， インコーポレイテッド | 多量体コード核酸及びその使用 |
| WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
| WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| JP7246930B2 (ja) | 2016-05-18 | 2023-03-28 | モデルナティエックス インコーポレイテッド | インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用 |
| JP7145579B2 (ja) | 2016-06-09 | 2022-10-03 | キュアバック アーゲー | 核酸カーゴ用のハイブリッド担体 |
| US10835583B2 (en) | 2016-06-13 | 2020-11-17 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency |
| JP2019525901A (ja) | 2016-06-14 | 2019-09-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 脂質ナノ粒子の安定化製剤 |
| EP3481430A4 (en) | 2016-07-11 | 2020-04-01 | Translate Bio Ma, Inc. | NUCLEIC ACID CONJUGATES AND USES THEREOF |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| JP2020501545A (ja) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのｒｎａ |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| US11464847B2 (en) | 2016-12-23 | 2022-10-11 | Curevac Ag | Lassa virus vaccine |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
| KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| WO2018172556A1 (en) | 2017-03-24 | 2018-09-27 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| WO2018200892A1 (en) | 2017-04-27 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS |
| ES2981244T3 (es) | 2017-04-28 | 2024-10-07 | Acuitas Therapeutics Inc | Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos |
| MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| KR20200024905A (ko) | 2017-07-04 | 2020-03-09 | 큐어백 아게 | 신규 핵산 분자 |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| EP3668834B1 (en) | 2017-08-17 | 2024-10-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR PREPARING MODIFIED RNA |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| RU2020115287A (ru) * | 2017-10-19 | 2021-11-19 | Куревак Аг | Новые молекулы искусственных нуклеиновых кислот |
| CN111511924A (zh) | 2017-11-08 | 2020-08-07 | 库瑞瓦格股份公司 | Rna序列调整 |
| US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
| AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| US11525158B2 (en) | 2017-12-21 | 2022-12-13 | CureVac SE | Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| US20210024907A1 (en) * | 2018-03-27 | 2021-01-28 | Factor Bioscience Inc. | Nucleic acid-based therapeutics |
| MX2020010941A (es) | 2018-04-17 | 2021-01-29 | Curevac Ag | Moleculas y composiciones novedosas de arn de vsr para vacunacion. |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
| EP3917656A1 (en) | 2019-01-31 | 2021-12-08 | Modernatx, Inc. | Vortex mixers and associated methods, systems, and apparatuses thereof |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN114207134A (zh) | 2019-03-25 | 2022-03-18 | 俄亥俄州国家创新基金会 | 工程化的mRNA序列及其用途 |
| CN112190591B (zh) * | 2019-07-08 | 2021-12-17 | 中国农业科学院兰州兽医研究所 | 核糖体蛋白rpl13抑制剂在制备抑制ires-依赖性翻译的病毒复制的药物中的应用 |
| WO2021154763A1 (en) | 2020-01-28 | 2021-08-05 | Modernatx, Inc. | Coronavirus rna vaccines |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
| CN115551545A (zh) | 2020-02-07 | 2022-12-30 | 摩登纳特斯有限公司 | SARS-COV-2 mRNA结构域疫苗 |
| WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| CA3178455A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
| WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
| WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
| CN111621588A (zh) * | 2020-06-08 | 2020-09-04 | 华中农业大学 | 光亮果皮番茄品种选育的分子标记及其应用 |
| WO2022002040A1 (en) | 2020-06-30 | 2022-01-06 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| US11976019B2 (en) | 2020-07-16 | 2024-05-07 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| EP4168391A1 (en) | 2020-08-20 | 2023-04-26 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| WO2022067010A1 (en) | 2020-09-25 | 2022-03-31 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| CN114717230B (zh) * | 2021-01-05 | 2024-09-03 | 麦塞拿治疗(香港)有限公司 | 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
| CN114717238A (zh) * | 2021-01-05 | 2022-07-08 | 麦塞拿治疗(香港)有限公司 | 表皮生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| WO2022152141A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
| WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| JP2024503698A (ja) | 2021-01-15 | 2024-01-26 | モデルナティエックス インコーポレイテッド | 変異型株ベースのコロナウイルスワクチン |
| EP4277653A1 (en) | 2021-01-15 | 2023-11-22 | ModernaTX, Inc. | Variant strain-based coronavirus vaccines |
| WO2022197624A1 (en) | 2021-03-15 | 2022-09-22 | Modernatx, Inc. | Therapeutic use of sars-cov-2 mrna domain vaccines |
| EP4322993A1 (en) | 2021-04-13 | 2024-02-21 | ModernaTX, Inc. | Respiratory virus combination vaccines |
| AU2022258463A1 (en) | 2021-04-14 | 2023-11-23 | Modernatx, Inc. | Influenza-coronavirus combination vaccines |
| WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
| KR20240013087A (ko) | 2021-05-24 | 2024-01-30 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | 지질 화합물 및 지질 나노입자 조성물 |
| JP2024528418A (ja) | 2021-06-18 | 2024-07-30 | サノフイ | 多価インフルエンザワクチン |
| CN117999355A (zh) | 2021-08-24 | 2024-05-07 | 生物技术欧洲股份公司 | 体外转录技术 |
| WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| JP2024533865A (ja) | 2021-09-14 | 2024-09-12 | レナゲード セラピューティクス マネージメント インコーポレイテッド | 環状脂質及びその使用方法 |
| AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
| CN116064598B (zh) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
| AU2022358824A1 (en) | 2021-10-08 | 2024-04-11 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
| KR20240107146A (ko) | 2021-11-05 | 2024-07-08 | 사노피 | 호흡기 세포융합 바이러스 rna 백신 |
| WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| CA3238764A1 (en) | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
| CA3239417A1 (en) | 2021-11-30 | 2023-06-08 | Yvonne CHAN | Human metapneumovirus vaccines |
| EP4444345A2 (en) | 2021-12-08 | 2024-10-16 | ModernaTX, Inc. | Herpes simplex virus mrna vaccines |
| AU2022413622A1 (en) | 2021-12-17 | 2024-08-01 | Sanofi | Lyme disease rna vaccine |
| CA3241014A1 (en) | 2021-12-20 | 2023-06-29 | Munir MOSAHEB | Mrna therapeutic compositions |
| CA3241492A1 (en) | 2021-12-23 | 2023-06-29 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compound and lipid nanoparticle composition |
| WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
| WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
| WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
| TW202408567A (zh) | 2022-05-06 | 2024-03-01 | 法商賽諾菲公司 | 用於核酸疫苗之訊息序列 |
| WO2023217267A1 (zh) * | 2022-05-13 | 2023-11-16 | 上海瑞宏迪医药有限公司 | 包含utr的核酸构建体及其应用 |
| WO2023230481A1 (en) | 2022-05-24 | 2023-11-30 | Modernatx, Inc. | Orthopoxvirus vaccines |
| WO2024015890A1 (en) | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Norovirus mrna vaccines |
| WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
| WO2024044108A1 (en) | 2022-08-22 | 2024-02-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccines against coronaviruses |
| WO2024050483A1 (en) | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024094876A1 (en) | 2022-11-04 | 2024-05-10 | Sanofi | Methods for messenger rna tailing |
| WO2024094881A1 (en) | 2022-11-04 | 2024-05-10 | Sanofi | Respiratory syncytial virus rna vaccination |
| WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
| WO2024126809A1 (en) | 2022-12-15 | 2024-06-20 | Sanofi | Mrna encoding influenza virus-like particle |
| WO2024126847A1 (en) | 2022-12-15 | 2024-06-20 | Sanofi | Mrna recombinant capping enzymes |
| WO2024133884A2 (en) | 2022-12-23 | 2024-06-27 | Sanofi | Optimized tailing of messenger rna |
| CN118574931A (zh) * | 2022-12-29 | 2024-08-30 | 传信生物医药(苏州)有限公司 | 一种新型5’-非翻译区元件及其应用 |
| CN116159127B (zh) * | 2023-01-17 | 2024-04-02 | 西安交通大学医学院第一附属医院 | 酸性核糖体蛋白p2在治疗焦虑症中的应用 |
| WO2024159172A1 (en) | 2023-01-27 | 2024-08-02 | Senda Biosciences, Inc. | A modified lipid composition and uses thereof |
| WO2024163465A1 (en) | 2023-01-30 | 2024-08-08 | Modernatx, Inc. | Epstein-barr virus mrna vaccines |
| CN116004696B (zh) * | 2023-02-01 | 2024-03-29 | 郑州贝贝生物科技有限公司 | 可与IRES组合的3ˊUTR加茎环结构基因及其应用、mRNA表达系统 |
| WO2024180262A1 (en) | 2023-03-02 | 2024-09-06 | Sanofi | Compositions for use in treatment of chlamydia |
| WO2024184489A1 (en) | 2023-03-07 | 2024-09-12 | Sanofi | Manufacture of messenger rna with kp34 polymerase |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024192277A2 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5908779A (en) | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| CA2285666C (en) | 1997-03-21 | 2010-12-14 | Enzo Therapeutics, Inc. | Vectors and viral vectors, and packaging cell lines for propagating same |
| AR024934A1 (es) * | 1999-07-27 | 2002-10-30 | Novartis Ag | Genes quimericos |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| EP2842964A1 (de) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
| US8021875B2 (en) | 2001-08-27 | 2011-09-20 | Roche Madison Inc. | Methods for expression of transgenes |
| WO2003038049A2 (en) | 2001-10-29 | 2003-05-08 | Renovis, Inc. | Method for isolating cell-type specific mrnas |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| EP1604011A4 (en) | 2003-01-21 | 2009-12-09 | Ptc Therapeutics Inc | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| SG147430A1 (en) * | 2003-10-10 | 2008-11-28 | Powderject Vaccines Inc | Nucleic acid constructs |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| GB0509965D0 (en) * | 2005-05-17 | 2005-06-22 | Ml Lab Plc | Improved expression elements |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| TR201909609T4 (tr) | 2005-08-23 | 2019-07-22 | Univ Pennsylvania | Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri. |
| CA2632900A1 (en) * | 2005-12-12 | 2007-06-21 | Research Corporation Technologies, Inc. | Hybrid 3' untranslated regions suitable for efficient protein expression in mammalian cells |
| DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| WO2008014979A2 (en) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| PL2176408T3 (pl) | 2008-01-31 | 2015-08-31 | Curevac Gmbh | Kwasy nukleinowe zawierające wzór (NuGiXmGnNv)a i ich pochodne jako środki immunostymulujące/ adiuwanty |
| WO2009155950A1 (en) * | 2008-06-27 | 2009-12-30 | King Faisal Specialist Hospital And Research Centre | Cloning-free method of generating transcriptionally and post-transcriptionally controllable expression active linear reporter constructs |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| AU2009298501A1 (en) * | 2008-09-30 | 2010-04-08 | Abbvie Inc. | Improved antibody libraries |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| JP5797190B2 (ja) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス， インコーポレイテッド | ワクチン免疫療法 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| BR112012024166A2 (pt) * | 2010-03-23 | 2022-09-27 | Intrexon Corp | Vetores condicionalmente expressando proteínas terapêuticas, células hospedeiras compreendendo os vetores, e usos dos mesmos |
| ES2558106T3 (es) | 2010-07-30 | 2016-02-02 | Curevac Ag | Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012030218A1 (en) * | 2010-09-01 | 2012-03-08 | Cellagenics B.V. | Nucleic acid fragments from a ribosomal protein promoter for enhancing gene expression |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| CA2866945C (en) * | 2012-03-27 | 2021-05-04 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| MX357803B (es) | 2012-03-27 | 2018-07-24 | Curevac Ag | Moléculas de ácido nucleico artificiales. |
| US9683233B2 (en) | 2012-03-27 | 2017-06-20 | Curevac Ag | Artificial nucleic acid molecules for improved protein or peptide expression |
| US20150306249A1 (en) | 2012-05-25 | 2015-10-29 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
| JP6896421B2 (ja) | 2013-08-21 | 2021-06-30 | キュアバック アーゲー | 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン |
| CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
| CA2927862C (en) * | 2013-12-30 | 2024-01-23 | Curevac Ag | Artificial nucleic acid molecules |
| JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
| SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
| ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
-
2014
- 2014-12-30 CA CA2927862A patent/CA2927862C/en active Active
- 2014-12-30 RU RU2016131391A patent/RU2717986C2/ru active
- 2014-12-30 JP JP2016543590A patent/JP6704850B2/ja active Active
- 2014-12-30 SG SG10201903381TA patent/SG10201903381TA/en unknown
- 2014-12-30 ES ES14854873T patent/ES2712092T3/es active Active
- 2014-12-30 DK DK14854873.8T patent/DK3090053T3/en active
- 2014-12-30 WO PCT/EP2014/003480 patent/WO2015101414A2/en active Application Filing
- 2014-12-30 AU AU2014375402A patent/AU2014375402B2/en active Active
- 2014-12-30 CN CN202010090980.4A patent/CN111304231A/zh active Pending
- 2014-12-30 SG SG11201603144QA patent/SG11201603144QA/en unknown
- 2014-12-30 CN CN201480065035.1A patent/CN105874072A/zh active Pending
- 2014-12-30 MX MX2016008551A patent/MX2016008551A/es active IP Right Grant
- 2014-12-30 BR BR112016014462A patent/BR112016014462A2/pt not_active Application Discontinuation
- 2014-12-30 KR KR1020167020951A patent/KR102399799B1/ko active IP Right Grant
-
2016
- 2016-06-27 MX MX2020003245A patent/MX2020003245A/es unknown
- 2016-06-28 US US15/195,934 patent/US10047375B2/en active Active
-
2020
- 2020-05-13 JP JP2020084213A patent/JP6997251B2/ja active Active
-
2022
- 2022-01-14 US US17/576,583 patent/US20220136001A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016008551A (es) | 2016-09-26 |
| CN111304231A (zh) | 2020-06-19 |
| ES2712092T3 (es) | 2019-05-09 |
| DK3090053T3 (en) | 2019-02-25 |
| CN105874072A (zh) | 2016-08-17 |
| BR112016014462A2 (pt) | 2017-10-24 |
| SG11201603144QA (en) | 2016-07-28 |
| KR20160104062A (ko) | 2016-09-02 |
| CA2927862A1 (en) | 2015-07-09 |
| JP2020184995A (ja) | 2020-11-19 |
| RU2016131391A3 (es) | 2018-08-23 |
| CA2927862C (en) | 2024-01-23 |
| JP2017502670A (ja) | 2017-01-26 |
| RU2016131391A (ru) | 2018-02-02 |
| US20220136001A1 (en) | 2022-05-05 |
| JP6704850B2 (ja) | 2020-06-03 |
| WO2015101414A2 (en) | 2015-07-09 |
| KR102399799B1 (ko) | 2022-05-18 |
| US20170029847A1 (en) | 2017-02-02 |
| AU2014375402B2 (en) | 2020-10-01 |
| SG10201903381TA (en) | 2019-05-30 |
| RU2717986C2 (ru) | 2020-03-27 |
| WO2015101414A3 (en) | 2015-10-08 |
| JP6997251B2 (ja) | 2022-01-17 |
| US10047375B2 (en) | 2018-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003245A (es) | Moleculas artificiales de acido nucleico. | |
| MX2018001040A (es) | Moleculas de acido nucleico artificiales. | |
| MX2017008670A (es) | Moleculas artificiales de acido nucleico novedosas. | |
| MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
| MX358706B (es) | Moleculas de acido nucleico artificiales que comprenden un top 5´utr. | |
| MX362981B (es) | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. | |
| EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
| PH12018500964A1 (en) | Modified friedreich ataxia genes and vectors for gene therapy | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| PH12019500209A1 (en) | Methods and compositions for gene expression in plants | |
| EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
| BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
| MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
| WO2019135816A3 (en) | Novel nucleic acid modifiers | |
| MX2017004285A (es) | Indicador biologico. | |
| MX346923B (es) | Genes y proteinas para sintesis de alcanoil-coa. | |
| WO2016046234A3 (en) | Recombinant phe-free proteins for use in the treatment of phenylketonuria | |
| PH12018501317A1 (en) | Compositions and methods for efficient targeting of transgenes | |
| MX2021004391A (es) | Proteinas inteinas y usos de las mismas. | |
| MX2013011996A (es) | Metodos para regular la expresion de genes de sirtuina. | |
| NZ752941A (en) | Frataxin expression constructs | |
| EA201691981A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение | |
| MX2018005872A (es) | Profarmacos de acido nucleico. | |
| EA201491780A1 (ru) | Мутанты c-raf, придающие резистентность к ингибиторам raf | |
| PH12019502442A1 (en) | Variants of human bmp7 protein |